EARLY PROSTATE CANCER DIAGNOSIS AND INTERVENTION

Halo Diagnostics is Your Partner in Early Diagnosis and Intervention

 

LEARN MORE ABOUT OUR ADVANCED PROSTATE SOLUTIONS AND CLINICAL TRIAL

Halo Diagnostics in partnership with Desert Medical Imaging, a leader in medical imaging services since 1998, offers the most advanced prostate health solutions available through our Global Center for Innovation in Indian Wells, California. Whether you live locally or would like to visit our center from outside the area, our team will work to provide the best possible experience. 

Prostate cancer detection, diagnosis and treatment is an ever evolving field. Gone are the days of solely relying on PSA tests, Digital Rectal Exams (DRE) and blind TRUS biopsies with biopsy cores taken randomly.

If your doctor suspects prostate cancer, as a result of a rise in PSA, positive DRE or urinary symptoms, a multi-parametric MRI (mpMRI) scan of the prostate can be used to identify suspicious areas.

If a suspicious area is found, we can perform a targeted MRI-guided biopsy. This approach provides greater accuracy in diagnosis with fewer needle cores, resulting in less pain and a lower risk of infection. A multi-parametric MRI scan and MRI guided biopsy are invaluable tools for treatment planning, no matter which course of treatment you choose.

Call us today or share your information to hear more about this program.

(760) 469-8111

 
 

PROSTATE CANCER CLINICAL TRIAL

Prostate Cancer Clinical Trial for Prostate Ablation in Patients with Localized Prostate Cancer

The purpose of this study is to obtain information on the effectiveness of transrectal delivered MRI guided Laser Focal Therapy. The system is designed to destroy prostate tissue under Magnetic Resonance Imaging (MRI) guidance using laser energy.

WHAT IS A CLINICAL STUDY?

A clinical study is a type of research study. Study staff will explain the clinical trial to you. Clinical trials include only people who choose to take part. If you have any questions, you can ask study staff for more explanation or visit: www.clinicaltrials.gov

HOW OFTEN WILL I BE SEEN?

After the procedure, you will have an ultrasound of your bladder after 48 hours. After that your follow-up visits will be at 6 months and 1 year. PSA testing and surveys will be done at 3 months, 2 years, 3 years and annually for 20 years. This protocol is to track and study rates of biochemical recurrence and metastasis.

WHAT IS THE PROCEDURE?

The laser focal therapy procedure (also called LITT or FLA) is designed to destroy prostate tissue under Magnetic Resonance Imaging (MRI) guidance using laser energy. The laser device is FDA 510(k) cleared for clinical use for soft tissue necrotization. The planning system is FDA 510(k) cleared for MRI guided prostate biopsy. DMI is the first site in the world to combine the devices under IRB approved clinical trial NCT 02243033.

ARE THERE ANY RISKS?

As with many procedures, there are some risks associated with laser focal therapy which can include: pain, bleeding, infection, decrease in seminal fluid volume, incontinence and erectile dysfunction. Study staff will review all the risks associated with the procedure with you and address any questions or concerns.

WHO CAN JOIN THIS STUDY

You can take part in this study of follow up if you are age 45 or older and have been diagnosed with prostate cancer that is low to intermediate risk and is confined to your prostate gland or have recurrent prostate cancer. There are also additional criteria for participating in this study. Study staff will review the full list with you. Approximately 1000 men will participate in this study.

 

Call us today or share your information to hear more about this program.

(760) 469-8111

 

SCHEDULE A CONSULTATION

We are always here for you! Contact us to schedule an appointment or to talk to one of our clinicians.
EMAIL at contact@halodx.com

 

MEET OUR SPECIALISTS

Our Team of Qualified Health Care Providers

 

DR. JOHN FELLER

Chief Medical Officer, Halo Dx
Board Certified Diagnostic Radiologist
In a first in the world outpatient facility recent innovation, Dr. Feller developed a prostate cancer detection and treatment program which uses MRI to guide biopsies of the prostate and MR-guided Focal Laser Ablation to detect and remove tumors on an outpatient basis, offers patients safe treatment with less recovery time and excellent outcomes.

Dr. John Feller is a pioneer in the evolving field of investigational prostate therapy.
The first case of focal laser ablation in the world was performed by Dr. John Feller in May, 2010 as part of a Phase I Clinical Trial.

FREQUENTLY ASKED QUESTIONS

HOW DO I DECIDE IF MPMRI IS A GOOD OPTION FOR ME?

mpMRI may be a good option for you if you have 
A. Clinical suspicion of prostate cancer 
Prostate-specific antigen (PSA) levels in the blood >4 ng/ml, abnormal digital rectal exam, and no prior history of prostate biopsy
Active surveillance in patients with Gleason score 6 or grade group 1 and PSA <10 ng/ml
B. Managing prostate cancer in patients post-treatment
Monitoring patients with biochemical recurrence of prostate cancer following treatment (prostatectomy or radiation)

WHAT ARE THE ADVANTAGES OF IMAGING-GUIDED BIOPSY OVER CONVENTIONAL TRUS BIOPSY?

Imaging-guided biopsy has the following advantages 
The MRI-guided biopsy is specific targeting of tumor suspicious region instead of random sampling (TRUS biopsy can miss aggressive cancer lesions about 30-35% of the time)
Minimally invasive with fewer cores (3-4) instead of 12 core TRUS Bx
Reduced chances of infection
Increased sensitivity of detecting aggressive lesions with decreased potential for detecting indolent disease.  This reduces overtreatment and prevents the psychological burden with misclassification of cancer stage

WHAT SHOULD I EXPECT BEFORE THE (MR-GUIDED) BIOPSY PROCEDURE?

Most patients visiting the clinic are concerned about the actual procedure and what it entails. 
At DMI we believe in providing care with advanced technology. 
Patients can request a consultation with one of our expert clinicians to address questions and uncertainties around the procedure. 
Prior to the procedure, they are also provided an informed consent form that details the risks and benefits. 
Patients are recommended to discontinue anticoagulants at least five days before the biopsy. 
Antibiotics are administered during the biopsy to avoid any infection or inflammation. We use numbing jelly to make sure the patients have an overall comfortable experience.

WHAT IS GLEASON SCORE?

Gleason score is an indicator of prostate cancer condition - higher scores mean more aggressive cellular architecture (think of golf scores!).

It is the sum of two numbers, Primary Gleason Grade and Secondary Gleason Grade, ranging from 1-5 that indicate the pathology of the cells in the tumor. A lower number indicates that the biopsy is closer to normal tissue and vice versa. 


The Gleason Scores (sum of Grades) range between 6-10 and describe the aggressiveness of the disease. Higher scores (8 and above) predict that cancers might grow and/or spread quickly. A Gleason score 7 (4+3/ 3+4) suggests intermediate risk with 4+3 being at a higher risk of progression than 3+4 (as the 4 pattern is dominant).

DO YOU OFFER FREE HEALTH CONSULTATIONS?

Yes, our health experts are available to provide free consultation and answer your questions prior to the procedures. Contact our experts TODAY!

 

Hear From Our Patients!

When my first Urologist suggested I use his procedure to remove my prostate, I decided to look for other alternatives. In my search, I came across this ablation procedure and thought that it would work best for me. I contacted DMI and set up and appointment and after initial testing and imaging, decided to go with it. I’m so glad I did. It’s been 10 months since my procedure and PSA is down to 1.4 now, and the images show a clean and healthy prostate gland. Everyone on the staff and those who worked directly with have been an absolute joy to work with.

M.E.F., Scottsdale, AZ

Since April 1 when Dr. May located the small tumor in the left anterior lobe, a second tumor had started in the right anterior lobe. Because of early detection by the MRI biopsy, the cancer was contained and removed before it had a chance to spread. Several of my physician friends have confirmed that it was very rare to detect such an aggressive cancer in the anterior lobe this early and the routine ultrasound biopsy would not have caught it. Months of waitful watching could have been deadly.

B.K., Springfield, Illinois

 

©2020 by HALO Diagnostics